Daré Bioscience, Inc. (NASDAQ:DARE – Get Free Report) was the target of a large increase in short interest in September. As of September 30th, there was short interest totalling 38,800 shares, an increase of 9.6% from the September 15th total of 35,400 shares. Based on an average daily volume of 39,300 shares, the short-interest ratio is currently 1.0 days. Currently, 0.5% of the company’s stock are short sold.
Analyst Upgrades and Downgrades
Separately, Maxim Group reissued a “hold” rating on shares of Daré Bioscience in a research report on Wednesday, August 14th.
Get Our Latest Analysis on DARE
Daré Bioscience Trading Up 0.6 %
Daré Bioscience (NASDAQ:DARE – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The biotechnology company reported $1.52 EPS for the quarter, topping the consensus estimate of ($0.57) by $2.09. The company had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.60 million. Analysts forecast that Daré Bioscience will post -0.27 earnings per share for the current year.
Institutional Inflows and Outflows
An institutional investor recently raised its position in Daré Bioscience stock. Renaissance Technologies LLC increased its holdings in shares of Daré Bioscience, Inc. (NASDAQ:DARE – Free Report) by 2.1% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 778,700 shares of the biotechnology company’s stock after buying an additional 15,800 shares during the quarter. Renaissance Technologies LLC owned 9.25% of Daré Bioscience worth $262,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 6.70% of the company’s stock.
Daré Bioscience Company Profile
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Featured Articles
- Five stocks we like better than Daré Bioscience
- EV Stocks and How to Profit from Them
- Taiwan Semiconductor Soars on Earnings With More Room to Run
- Health Care Stocks Explained: Why You Might Want to Invest
- Is Lucid Group Nearing the Bottom? What Investors Should Know
- What is a Dividend King?
- 90% Gain Possible? Analysts Are Bullish on Joby Aviation
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.